venBio Partners LLC Long-Term Concentrated

Location: San Francisco, CA

CIK: 0001776382 · Show all filings

Period: Q3 2021 (← Previous) (Next →)

Filing Date: Nov 15, 2021

Total Value: $1.004B (100.0% shares, 0.0% debt)

Holdings (9)

ALXO ALX ONCOLOGY HLDGS INC 71.4%

Value $716M Shares 9,699,925 Est. Cost $39.31 Unrealized +69.6%

HRMY HARMONY BIOSCIENCES HLDGS IN 11.7%

Value $117M Shares 3,063,194 Est. Cost $36.46 Unrealized -11.7%

— AKERO THERAPEUTICS INC 4.9%

Value $49.19M Shares 2,200,778 Est. Cost $19.15 Unrealized —

PHVS PHARVARIS N V 4.1%

Value $40.84M Shares 2,303,310 Est. Cost $31.46 Unrealized -45.6%

— IMPEL NEUROPHARMA INC 3.3%

Value $33.61M Shares 2,759,791 Est. Cost $8.85 Unrealized —

— ELEVATION ONCOLOGY INC 2.0%

Value $20.32M Shares 2,608,167 Est. Cost $13.57 Unrealized —

— CHECKMATE PHARMACEUTICALS IN 1.5%

Value $14.58M Shares 3,673,374 Est. Cost $11.51 Unrealized —

— METACRINE INC 1.0%

Value $10.49M Shares 3,059,123 Est. Cost $10.21 Unrealized —

— VERONA PHARMA PLC 0.1%

Value $887K Shares 161,897 Est. Cost $9.65 Unrealized —

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
ALXO	ALX ONCOLOGY HLDGS INC	9,699,925	$716M	71.4%	$39.31	+69.6%	COM	00166B105
HRMY	HARMONY BIOSCIENCES HLDGS IN	3,063,194	$117M	11.7%	$36.46	-11.7%	COM	413197104
—	AKERO THERAPEUTICS INC	2,200,778	$49.19M	4.9%	$19.15	—	COM	00973Y108
PHVS	PHARVARIS N V	2,303,310	$40.84M	4.1%	$31.46	-45.6%	COM	N69605108
—	IMPEL NEUROPHARMA INC	2,759,791	$33.61M	3.3%	$8.85	—	COM	45258K109
—	ELEVATION ONCOLOGY INC	2,608,167	$20.32M	2.0%	$13.57	—	COM	28623U101
—	CHECKMATE PHARMACEUTICALS IN	3,673,374	$14.58M	1.5%	$11.51	—	COM	162818108
—	METACRINE INC	3,059,123	$10.49M	1.0%	$10.21	—	COM	59101E103
—	VERONA PHARMA PLC	161,897	$887K	0.1%	$9.65	—	SPONSORED ADS	925050106